Abstract
Clinical and immunological analysis of the efficiency of combined immunotherapy with the use dendritic cells for the treatment of malignant glioma of the brain was carried out. Dendritic cells generated in the presence of granulocyte-macrophage CSF and IFN-α retain their functional characteristics in patients with gliomas, which suggests the possibility of their use for the treatment of malignant tumors (glioma) of the brain. Combined therapy using interferon-induced dendritic cells was associated with generation of antigen-specific immune response during vaccinations. The results indicate satisfactory tolerance of combined immunotherapy using dendritic cells and the absence of toxic side effects at the stage of adoptive immunotherapy and at the stage of vaccinations with dendritic cells. Clinical trials showed that vaccinations with dendritic cells included into combined immunotherapy improved the quality of life and survival of patients with malignant gliomas.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
O. Yu. Leplina, M. A. Tikhonova, Yu. P. Kozlov, et al., Med. Immunol., 7, No. 4, 365–374 (2005).
V. P. Lozovoi and V. S. Kozhevnikov, Methods for Evaluating Cellular Effector Functions of Delayed-Type hypersensitivity. Methodological Recommendations [in Russian], Moscow (1990), pp. 1–10.
A. A. Ostanin, M. I. Tsentner, N. A. Khonina, et al., Vopr. Onkol., 49, No. 2, 170–175 (2003).
E. R. Chernykh, V. V. Stupak, M. I. Tsentner, et al., Med. Immunol., 4, Nos. 4–5, 588–592 (2002).
E. R. Chernykh, V. V. Stupak, M. I. Tsentner, et al., Sibirsk. Onkol. Zh., Nos. 2–3, 85–88 (2004).
Y. Akasaki, T. Kikuchi, S. Homma, et al., J. Immunother., 24, No. 2, 106–113 (2001).
J. Banchereau and R. M. Steinman, Nature, 392, 245–252 (1998).
S. Della Bella, S. Nicola, A. Riva, et al., J. Leukoc. Biol., 75, No. 1, 106–116 (2004).
R. A. Feinstermaker and M. J. Ciesielski, Cancer Control, 11, No. 3, 181–190 (2004).
T. Kikuchi, Y. Akasaki, M. Irie, et al., Cancer Immunol. Immunother., 50, No. 7, 337–344 (2001).
M. F. Lipscomb and B. J. Masten, Physiol. Rev., 82, No. 1, 97–130 (2002).
S. Parlato, S. M. Santini, C. Lapenta, et al., Blood, 98, No. 10, 3022–3029 (2001).
W. F. Pickl, O. Majdic, P. Kohl, et al., J. Immunol., 157, No. 9, 3850–3859 (1996).
S. M. Santini, C. Lapenta, M. Logozzi, et al., J. Exp. Med., 191, No. 10, 1777–1788 (2000).
S. M. Santini, T. Di Pucchio, C. Lapenta, et al., Stem Cells, 21, No. 3, 357–362 (2003).
S. M. Santini and F. Belardelli, Ibid., 21, No. 4, 495–505 (2003).
S. A. Soling and N. G. Rainov, Mol. Med., 7, No. 10, 659–667 (2001).
B. Thurner, C. Roder, D. Dieckmann, et al., J. Immunol. Methods, 223, No. 1, 1–15 (1999).
B. A. Tjoa and M. L. Salgaller, Expert Opin. Investig. Drugs, 9, No. 9, 2093–2102 (2000).
R. Yamanaka, J. Homma, N. Yajima, et al., Clin. Cancer Res., 11, No. 11, 4160–4167 (2005).
R. Yamanaka, N. Yajima, T. Abe, et al., Int. J. Oncol., 23, No. 1, 5–15 (2003).
S. Yoshida, K. Morii, M. Watanabe, et al., Cancer Immunol. Immunother., 50, No. 6, 321–327 (2001).
J. S. Yu, C. J. Wheeler, P. M. Zeltzer, et al., Cancer Res., 61, No. 3, 842–847 (2001).
Author information
Authors and Affiliations
Corresponding author
Additional information
__________
Translated from Kletochnye Tehnologii v Biologii i Medicine, No. 2, pp. 92–98, April, 2007
Rights and permissions
About this article
Cite this article
Leplina, O.Y., Stupak, V.V., Kozlov, Y.P. et al. Use of interferon-α-induced dendritic cells in the therapy of patients with malignant brain gliomas. Bull Exp Biol Med 143, 528–534 (2007). https://doi.org/10.1007/s10517-007-0172-1
Received:
Issue Date:
DOI: https://doi.org/10.1007/s10517-007-0172-1